JP7587218B2 - 軽度認知障害治療剤 - Google Patents

軽度認知障害治療剤 Download PDF

Info

Publication number
JP7587218B2
JP7587218B2 JP2022521858A JP2022521858A JP7587218B2 JP 7587218 B2 JP7587218 B2 JP 7587218B2 JP 2022521858 A JP2022521858 A JP 2022521858A JP 2022521858 A JP2022521858 A JP 2022521858A JP 7587218 B2 JP7587218 B2 JP 7587218B2
Authority
JP
Japan
Prior art keywords
cilostazol
opc
cognitive impairment
dementia
mild cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022521858A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021230131A5 (https=
JPWO2021230131A1 (https=
Inventor
大輔 川上
匡史 猪原
聡 齊藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shimadzu Corp
National Cerebral and Cardiovascular Center
Original Assignee
Shimadzu Corp
National Cerebral and Cardiovascular Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shimadzu Corp, National Cerebral and Cardiovascular Center filed Critical Shimadzu Corp
Publication of JPWO2021230131A1 publication Critical patent/JPWO2021230131A1/ja
Publication of JPWO2021230131A5 publication Critical patent/JPWO2021230131A5/ja
Priority to JP2024189461A priority Critical patent/JP2025010627A/ja
Application granted granted Critical
Publication of JP7587218B2 publication Critical patent/JP7587218B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2022521858A 2020-05-11 2021-05-06 軽度認知障害治療剤 Active JP7587218B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024189461A JP2025010627A (ja) 2020-05-11 2024-10-29 軽度認知障害治療剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020083163 2020-05-11
JP2020083163 2020-05-11
PCT/JP2021/017368 WO2021230131A1 (ja) 2020-05-11 2021-05-06 軽度認知障害治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024189461A Division JP2025010627A (ja) 2020-05-11 2024-10-29 軽度認知障害治療剤

Publications (3)

Publication Number Publication Date
JPWO2021230131A1 JPWO2021230131A1 (https=) 2021-11-18
JPWO2021230131A5 JPWO2021230131A5 (https=) 2023-04-12
JP7587218B2 true JP7587218B2 (ja) 2024-11-20

Family

ID=78525720

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521858A Active JP7587218B2 (ja) 2020-05-11 2021-05-06 軽度認知障害治療剤
JP2024189461A Pending JP2025010627A (ja) 2020-05-11 2024-10-29 軽度認知障害治療剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024189461A Pending JP2025010627A (ja) 2020-05-11 2024-10-29 軽度認知障害治療剤

Country Status (5)

Country Link
US (1) US20230270737A1 (https=)
EP (1) EP4151213A4 (https=)
JP (2) JP7587218B2 (https=)
CN (1) CN115551508A (https=)
WO (1) WO2021230131A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013187075A1 (ja) 2012-06-15 2013-12-19 公益財団法人先端医療振興財団 軽度認知障害の予防および／または治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
KR20120010800A (ko) * 2010-07-27 2012-02-06 인제대학교 산학협력단 실로스타졸 또는 이의 약리학적 허용가능한 염을 유효성분으로 함유하는 퇴행성 신경질환 치료 및 예방용 약학조성물
CN108430474A (zh) * 2015-12-25 2018-08-21 大塚制药株式会社 包含阿立哌唑和西洛他唑的药物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013187075A1 (ja) 2012-06-15 2013-12-19 公益財団法人先端医療振興財団 軽度認知障害の予防および／または治療剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FU, C.H. J., et al.，Journal of Chromatography B: Biomedical Sciences and Applications，1999年，Vol.728, No.2，pp.251-262.
LIU, Y., et al.，Cardiovascular Drug Reviews，2001年，Vol.19, No.4，pp.369-386.
MAKI, T., et al.，Annals of Clinical and Translational Neurology，2014年，Vol.1, No.8，pp.519-533.

Also Published As

Publication number Publication date
CN115551508A (zh) 2022-12-30
US20230270737A1 (en) 2023-08-31
WO2021230131A1 (ja) 2021-11-18
EP4151213A4 (en) 2024-05-29
EP4151213A1 (en) 2023-03-22
JP2025010627A (ja) 2025-01-22
JPWO2021230131A1 (https=) 2021-11-18

Similar Documents

Publication Publication Date Title
Moehrle et al. First‐in‐man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials
US12358870B2 (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
DIAMANT et al. The effect of montelukast (MK‐0476), a cysteinyl leukotriene receptor antagonist, on allergen‐induced airway responses and sputum cell counts in asthma
JP2012504649A (ja) 肝性脳症を治療する方法
Link et al. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping
Yin et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib
CN114269722B (zh) 麦角硫因、s-甲基-麦角硫因及其用途
CN104483407B (zh) 血样中微量伊马替尼测定方法及在零期临床试验中的应用
Fleishaker et al. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers
Stone et al. Frontiers in Alzheimer’s disease therapeutics
JP2008074852A (ja) 肝機能が低下した精神医学上の患者をパリペリドンで治療
JP7587218B2 (ja) 軽度認知障害治療剤
KR102105354B1 (ko) 당대사능의 측정 방법 및 그에 사용하는 조성물
BG64300B1 (bg) Използване на фанхинон за лечение на болестта на алцхаймер
Dilger et al. Chronopharmacology of intravenous and oral modified release verapamil
Xiong et al. The role of positron emission tomography imaging of β-amyloid in patients with Alzheimer's disease
Johansson et al. Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients
André et al. Delirium following ingestion of marijuana present in chocolate cookies
KR20190030691A (ko) 위험 환자에서 알츠하이머병의 예방에 사용하기 위한 옥사진 유도체
Smerikarova et al. A brief review of analytical methods for the estimation of ttr kinetic stabilizers in pharmaceutical formulations and biological matrices
Takagi et al. Comparative studies on interaction between theophylline and quinolones
WO2007119771A1 (ja) ディスペプシア診断検査薬
US10722518B2 (en) Oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy
Kim et al. Pharmacokinetic comparisons of bepotastine besilate and bepotastine salicylate in healthy subjects
CA3117563C (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221107

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20230119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241028

R150 Certificate of patent or registration of utility model

Ref document number: 7587218

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150